SHARES: DOWN
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.ICI's shares fell 13 per cent and its earnings forecasts were shaved in the wake of its failure to sell its Crosfield subsidiary and on concern over debt levels. US-based WR Grace & Co. is not to go ahead with an agreed offer of $455m (pounds 268m) for Crosfield, first announced in April, because of regulatory problems. The sale was aimed at cutting ICI's pounds 4.4bn debt and was part of ICI's transformation into a speciality chemical company from its focus on commodity chemicals.
The stalled sale comes amid falling asset values across the chemical industry, prompted by emerging-market recessions, fueling speculation that Grace sought to renegotiate the price for Crosfield. Copyright: IOS & Bloomberg
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments